About CellVir

About company

CellVir, founded in March 2006, is developing a new generation of anti-retrovirals based on a novel therapeutic mode of action. Instead of targeting the inhibition of the catalytic activity of viral enzymes (as do most of today's drugs), CellVir's approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this novel mode of action offer two key potential advantages: complementarity to existing drugs because of their lack of susceptibility to cross resistance mechanisms, and a reduced occurrence of viral mutations that lead to drug resistance.